Single nucleus RNA-sequencing reveals altered intercellular communication and dendritic cell

activation in nonobstructive hypertrophic cardiomyopathy

Christina J. Codden[1], Amy Larson[1], Junya Awata[1], Gayani Perera[1] and Michael T. Chin[1,2,*]

[1]Molecular Cardiology Research Institute, Tufts Medical Center, Boston, MA, USA

[2]Hypertrophic Cardiomyopathy Center, Tufts Medical Center, Boston, MA, USA

*To whom correspondence should be addressed

Michael T. Chin, MD, PhD

Molecular Cardiology Research Institute

Tufts Medical Center

800 Washington Street, Box 80

Boston, MA 02111

T: 617 636 8776

F: 617 636 5999

The authors have declared that no conflict of interest exists.

Abstract

End stage, nonobstructive hypertrophic cardiomyopathy (HCM) is an intractable condition with

no disease-specific therapies. To gain insights into the pathogenesis of nonobstructive HCM, we

performed single nucleus RNA-sequencing (snRNA-seq) on human HCM hearts explanted at the

time of cardiac transplantation and organ donor hearts serving as controls. Differential gene

expression analysis revealed 64 differentially expressed genes linked to specific cell types and

molecular functions. Analysis of ligand-receptor pair gene expression to delineate potential

intercellular communication revealed significant reductions in expressed ligand-receptor pairs

affecting the extracellular matrix, growth factor binding, peptidase regulator activity, platelet-

derived growth factor binding and protease binding in the HCM tissue. Changes in Integrin-β1

receptor expression were responsible for many changes related to extracellular matrix

interactions, by increasing in dendritic, smooth muscle and pericyte cells while decreasing in

endothelial and fibroblast cells, suggesting potential mechanisms for fibrosis and microvascular

disease in HCM and a potential role for dendritic cells. In contrast, there was an increase in

ligand-receptor pair expression associated with adenylate cyclase binding, calcium channel

molecular functions, channel inhibitor activity, ion channel inhibitor activity, phosphatase

activator activity, protein kinase activator activity and titin binding, suggesting important shifts

in various signaling cascades in nonobstructive, end stage HCM.

Brief summary

End stage, nonobstructive human HCM is associated with altered intercellular communication

and dendritic cell activation, providing novel insights into potential disease mechanisms.

Introduction

Hypertrophic Cardiomyopathy (HCM) is an inherited disorder characterized by unexplained left ventricular hypertrophy, often asymmetric, often involving the interventricular septum, often associated with left ventricular outflow tract (LVOT) obstruction, fibrosis, microvascular occlusion, and sudden cardiac death. Genetic studies have identified numerous causal mutations in a variety of sarcomere genes such as *MYH7*, *MYL2, MYL3*, *MYBPC3*, *TNNT2*, *TNNI3* and *TPM1*, leading to the concept that HCM is a disease of the sarcomere [1], but genetic testing is only informative in approximately 30% of probands, indicating that other genes and factors significantly contribute to the HCM phenotype. Recently, it has been recognized that in most cases HCM can be considered polygenic with multiple loci contributing to the phenotype or in some cases acting as modifiers of existing sarcomere mutations, by affecting modifiable risk factors such as diastolic blood pressure [2-4]. Patients with sarcomere gene mutations have been found to have more adverse events than those without sarcomere mutations [5], thus implicating a need for better understanding of distinct pathogenic steps in these two groups. The development of fibrosis is associated with an increased risk of sudden cardiac death and is a poor prognostic factor [6-11]. Excess deposition of extracellular matrix (ECM) proteins can cause cardiac stiffening, which can impede contraction [6]. It can additionally disrupt electrical coupling, heightening patient susceptibility to arrhythmogenesis. In the end-stages of disease, fibrosis replaces up to 50% of the myocardium and is a key determinant of patient outcome [9-11].

Although LVOT obstruction is common and easily treatable in HCM, a subset of patients with

nonobstructive HCM develop progressive, symptomatic heart failure, despite guideline directed

medical therapy, often leading to heart transplantation [12]. Histopathological features include

myocyte hypertrophy, fibrosis, myocyte disarray and microvascular disease and are common

with obstructive HCM. The genetic profiles of patients with nonobstructive HCM are also

indistinguishable from those with obstructive HCM, raising questions about the sources of

asymmetric hypertrophy. Human tissue for study of nonobstructive HCM can only be obtained

postmortem or at the time of heart transplantation or other cardiac procedure.

Single cell and single nucleus transcriptomic analysis have facilitated an understanding of

cellular phenotypes and interactions occurring in complex tissues such as the heart and high

quality datasets of the normal human heart have been published [13-15]. We have recently

performed single nucleus RNA-seq analysis of obstructive HCM and found significant alterations

in intercellular communication pathways that affect the extracellular matrix, involving integrin-

β1, thus providing a potential mechanism linking sarcomere dysfunction to extracellular matrix

signaling [16]. Here, we analyze single nucleus transcriptomes in tissue from nonobstructive, end

stage HCM and compare with normal tissue. As with obstructive HCM, we find that alterations

in intercellular communication pathways affecting the extracellular matrix involve integrin-β1,

but there are additional alterations in communication between fibroblasts, vascular cells, and

dendritic cells not seen in obstructive HCM. In addition, there are increases in various molecular

functions associated with adenylate cyclase signaling, ion channel function, protein

phosphatase and protein kinase activity, suggesting a unique intercellular signaling milieu

specific to nonobstructive HCM. These findings have important implications for the

development of novel therapies for nonobstructive HCM.

Results

Patient characteristics

Explanted heart tissue was obtained from six HCM patients with severely symptomatic,

nonobstructive, end stage disease who underwent cardiac transplantation. Patient

characteristics are summarized in Table 1. Patients gave informed consent for their heart tissue

to be used in research. The patients varied in age from 25 to 67. Five of six patients were

female. Two of the patients carried pathogenic MYH7 mutations and the remaining four

patients had no known mutations pathogenic for HCM. Four organ donors and datasets for the

normal human IVS have been previously described [15] and are summarized in Table 2 with the

two additional donors used in this study.

Nonobstructive HCM IVS tissue reveals extensive cardiomyocyte and fibroblast diversity

After sequencing and initial data processing with Cell Ranger software [17], each sample dataset

was processed further to remove called nuclei that were likely droplets with ambient RNA, or

droplets that contained two nuclei. The six HCM datasets and six donor heart datasets were

combined into one dataset using the Seurat Integration function [18]. The final combined dataset

included 49010 nuclei from nonobstructive HCM hearts and 34358 nuclei from donor hearts.

Clustering of the integrated dataset revealed 22 cell populations within the IVS which was

visualized using the dimensionality reduction algorithm uniform manifold approximation and

projection (UMAP, Fig. 1A). Each point represents a single nucleus colored by cluster identity.

Visualizing the integrated dataset by Normal and HCM datasets reveals that all 22 clusters are

present in each condition and all samples contribute to all clusters (Fig. 1B, C, D). No cell

populations (i.e., clusters) were specific to either condition.

Cell identities were assigned to each cluster using known gene markers of expected cell types,

differentially expressed genes queried against panglaoDB [19], gene ontology (GO) using GOstats

[20], and Ingenuity Pathway Analysis [21]. Supplemental Table 1 lists the gene markers used to

identify each cell type. Supplemental Table 2 lists the consensus cell identity assignment using

all four methods. Upon assigning cell types, we found that similar cell types expressed similar

markers and the associated clusters were expectedly positioned close to each other in UMAP

space (Fig. 2A, B). Interestingly, we see ten cardiomyocyte populations (i.e., clusters) and six

fibroblast populations, revealing significant cardiomyocyte and fibroblast diversity in the IVS

(Fig. 2A, 2B), consistent with previous reports [15, 16]. Other cell types identified included

endothelial, smooth muscle, pericyte, neuronal, leukocyte, and dendritic cell populations.

Among normal donor heart samples, assigned cardiomyocytes made up approximately 48.5% of

the total cell population. Similarly, among nonobstructive HCM samples cardiomyocytes made

up approximately 55.0% of the total cell population. Noncardiomyocytes make up the

remaining cell population. Nonobstructive HCM does not appear to be associated with a shift in

the relative proportion of cells in the heart.

131 **Trajectory analysis and differential gene expression analysis reveal nonobstructive HCM-**

132 **associated perturbations**

133 Clustering analysis revealed diversity of both cardiomyocytes and fibroblasts. To gain insight

134 into the potential relationships among the different cell populations for each cell type, clusters

135 were projected onto pseudotime trajectory analysis using Monocle3 [22]. Trajectory analysis was

136 performed on Normal cells only, nonobstructive HCM cells only, and both conditions combined

137 for each of the 8 cell types identified in the above analysis. In single-cell trajectory analysis, a

138 trajectory is a computed path that describes a cell type's biological progression through a

139 dynamic process. Prior to building trajectory paths, the root node, or beginning, of each

140 trajectory path was determined through hierarchical clustering of our single nuclei data by cell

141 type. Then, trajectory paths for each assigned cell type (assigned in Seurat) were constructed in

142 UMAP space using Monocle3 with Normal and HCM data together and individually. Once

143 trajectory paths were established, pseudotime could be assigned to each cell. For all cell types,

144 root nodes showed consistent placement among Normal only groups, HCM only groups, and

145 Normal and HCM groups. Trajectory paths also showed similar basic structures among Normal

146 only groups, HCM only groups, and Normal and HCM group (data not shown). Therefore, we

147 were not able to distinguish any meaningful changes among trajectory paths. These findings

148 suggest that the relationships between the various subtypes of each cell type do not vary

149 significantly in nonobstructive HCM heart tissue in comparison to Normal heart tissue, as we

150 have reported for obstructive HCM [16].

151

Establishment of trajectories facilitates the analysis of differential gene expression along the

trajectory and between conditions along the trajectory. We analyzed differential gene

expression for each cell type along their trajectories for the Normal and HCM populations.

Differential expression analysis between Normal and HCM cells by assigned cell type and cluster

was performed in which generalized linear regression models were fit for each gene. Resulting

coefficients were tested for significant differences from zero, with an adjusted p-value cutoff

≤0.05 using the Wald Test. No differentially expressed genes were detected by this method.

Differential gene expression can also be analyzed along trajectory paths in UMAP space through

spatial autocorrelation. Moran's I statistic and adjusted p-values were calculated for each gene

in Normal only and HCM only groups within each cell type. When paired with a significant p-

value ($\leq$0.05), a Moran's I statistic value near zero indicated no spatial autocorrelation and a

value near 1 indicated perfect positive autocorrelation in which a gene is expressed in a focal

region of the UMAP space. Results showed between 115 and 6695 genes are differentially

expressed along trajectory paths among cell types and between 18 and 4518 differentially

expressed genes overlapped between Normal and HCM groups among cell types (Supplemental

Table 3).

Since many genes showed differential expression over UMAP space, further conservative

filtering was performed to identify genes of interest. Genes with Moran's I statistic available for

a single condition, Normal or HCM, were filtered by a Moran's I statistic value above 0.1, while

genes with Moran's I statistics available for both classes were filtered by an absolute difference

>0.1. For each cell type, 1 to 18 genes passed the filter with 64 unique genes in total passing the

filter among all cell types (Supplemental Table 4). The expression of these filtered genes was

then plotted in UMAP space for their associated cell type in Normal and HCM conditions as

shown for a subset of identified genes in cardiomyocytes (Supplemental Figure 1). Visual

analysis of the UMAP plots revealed 44 genes with pronounced differences in their spatial

expression between Normal and nonobstructive HCM conditions (summary in Table 3). Of these

44 genes, 3 (*MYH7, MYL2, TNNT2*) are already known to be associated with human HCM. GO

Enrichment analysis of these 44 differentially expressed genes revealed significant enrichment

for molecular functions involving actin binding, biological processes involving muscle

development and muscle differentiation and cellular components including the sarcomere,

myofibril and contractile fiber (Fig. 3A). Analysis of genes from this list showing increased

expression in nonobstructive HCM revealed significant enrichment in molecular functions

involving structural constituent of muscle and actin binding, no enriched biological processes

and enrichment in cellular components involving the sarcomere, myofibril and contractile fiber

(Fig. 3B). Analysis of genes from this list showing decreased expression in nonobstructive HCM

revealed enrichment for molecular functions involving lipid transport and the ECM structural

constituent, biological processes involving muscle differentiation, muscle development, lipid

transport and lipid localization, and cellular components involving the endoplasmic reticulum

membrane (Fig. 3C).

Ligand-receptor pair gene expression indicates alteration of intercellular communication in

HCM

HCM is associated with a general decrease in cell-cell communication but an increase in

fibroblast, smooth muscle cell and pericyte to dendritic communication and an increase in

smooth muscle cell to leukocyte communication

To quantify potential cardiac cell-cell communication in Normal and nonobstructive HCM IVS

tissue, we quantified the number of possible expressed ligand-receptor pairs among cell types

as previously described [16, 23]. We examined the expression of a curated list of 3627 unique

human ligand-receptor (L-R) pairs derived by combining a collection of 2557 human L-R pairs [24]

with another set of 3398 human L-R pairs [25] and eliminating duplicate pairs. Ligands and

receptors were considered expressed if their associated gene was detectable in ≥ 20% of cells in

a cell type. Notably, quantification of cell-cell communication in this study represents potential

communication as we account for only expressed ligand-receptor pairs and not the position or

boundaries of cell types. Results showed that nonobstructive HCM IVS tissue demonstrated a

reduced intercellular communication network among our 8 identified cell types compared to

normal IVS tissue (Fig. 4). Quantitatively, the total number of expressed ligand-receptor pairs in

the nonobstructive HCM tissue (n=405) was much lower than in Normal tissue (n=710, Fig. 4A,

B). Analysis of the broadcast ligands by individual cell types demonstrates that 1) all cells except

for smooth muscle cells show a broad decrease in both paracrine and autocrine ligand

broadcasting in nonobstructive HCM (Fig. 4B, C, D) and 2) fibroblasts broadcast the greatest

number of ligands to the other cell types in both Normal and nonobstructive HCM tissue.

Analysis of receptor expression again showed a broad decrease across cell types, except for

dendritic cells (Fig. 4B, C, D). Fibroblast communication is particularly high with fibroblast,

endothelial, pericyte, smooth muscle, neuronal, and cardiomyocyte cells (Fig. 4). While

intercellular communication was generally reduced in nonobstructive HCM tissue compared to

Normal tissue, there was several cases of increased nonobstructive HCM communication, from

fibroblasts, smooth muscle cells, pericytes and cardiomyocytes to dendritic cells and from

smooth muscle cells to leukocytes (Fig 4C, D).

Communication between fibroblasts and dendritic cells increased from 5 to 13 L-R pairs in

nonobstructive HCM tissue due primarily to the dendritic cells in nonobstructive HCM tissue

gaining *ITGB1* receptor expression to enable communication with several cognate ligands

(COL1A2, COL3A1, COL4A1, COL6A1, COL6A2, COL6A3, FN1, LAMA2, LGALS1, LUM;

Supplemental Table 5). The increase in smooth muscle cell to dendritic cell communication (3

to 9 L-R pairs) is also primarily due to dendritic cells in nonobstructive HCM tissue gaining *ITGB1*

receptor expression, to enable communication with several smooth muscle cell cognate ligands

(COL1A2, COL4A1, COL6A1, COL6A2, FN1, LGALS1; Supplemental Table 5). Similarly, increased

pericyte to dendritic cell interaction (3 to 8 L-R pairs) is also due primarily to nonobstructive

tissue dendritic cells gaining ITGB1 receptor expression, to enable communication with several

pericyte cognate ligands (COL1A2, COL4A1, COL6A1, COL6A2, FN1, LGALS1; Supplemental Table

5). The increase in smooth muscle cell to leukocyte communication in nonobstructive HCM (6 to

10 L-R pairs) is due to leukocytes gaining ITGB1 receptor expression, to enable communication

with several smooth muscle cell cognate ligands (COL1A2, COL4A1, COL6A1, COL6A2, FN1)

(Supplemental Table 6).

Changes in ligand-receptor pair gene expression imply alterations in molecular function

To assess the molecular functions potentially affected by changes in ligand-receptor signaling

among our 8 identified cell types, GO enrichment analysis was performed on the ligands and

receptors in expressed ligand-receptor pairs from both Normal and nonobstructive HCM tissue

(Fig. 5). We observed a decrease in most identified ligand molecular functions (34 of 47) in the

nonobstructive HCM heart tissue compared to the Normal heart tissue, with complete loss of

functions involving insulin receptor binding, insulin-like growth factor receptor binding,

lipoprotein particle receptor binding, and structural molecule activity conferring elasticity (note,

these are low count normal MFs; Figure 5A). Large decreases in nonobstructive molecular

functions relative to Normal (>100 count difference) were found for extracellular matrix

structural constituent, extracellular matrix structural constituent conferring tensile strength

(56%), growth factor binding (57%), peptidase regulator activity (75%), platelet-derived growth

factor binding (56%), protease binding (74%; Figure 5A). Large increases in molecular functions

in nonobstructive HCM tissue relative to normal tissue (>50 count difference) were noted for

adenylate cyclase binding, calcium channel inhibitor activity, calcium channel regulator activity,

channel inhibitor activity, protein kinase activator activity, protein N-terminus binding, protein

phosphatase activator activity, protein serine threonine kinase activator activity and titin

binding. When ligand molecular function is assessed in individual cell types, a general decrease

in most nonobstructive molecular functions is observed compared to the normal condition

(Figure 5B-I) with generally more drastic decreases in cardiomyocytes, endothelial cells,

dendritic cells, leukocytes, and neuronal cell ligand molecular functions (Figure 5). Less drastic

decreases and increases are observed in non-obstructive ligand molecular functions among

fibroblasts, pericytes, and smooth muscle cells (Figure 5).

Molecular functions associated with changes in receptor expression align with changes in ligand

expression (Fig. 6A) including the finding of a general decrease in most nonobstructive

molecular functions compared to the Normal condition (46 of 65 molecular functions; Figure 6).

The largest decreases (>100 count difference) in nonobstructive molecular functions compared

to Normal included amyloid beta binding, coreceptor activity, lipoprotein, peptide binding, and

scavenger receptor activity (Figure 6A). The largest increases (> 100 count difference) in

nonobstructive molecular functions relative to Normal included amide binding, calcium

molecular functions, calmodulin binding, channel/gated channel molecular functions, divalent

inorganic cation transmembrane transporter activity, metal ion transmembrane transporter

activity, protein kinase A activity, and sulfur compound binding (Figure 6A). Trends in receptor

molecular functions in individual cell types are notable for increases related to signal

transduction in dendritic cells and leukocytes, particularly calcium channel activity and protein

kinase A activity in dendritic cells.

Fibroblast subtypes show subtype-specific changes in cell-cell communication

To better understand the interaction between the different fibroblast populations and other

cell types in the IVS, we examined the potential ligand-receptor communication through cell

network plots for all fibroblast subtypes alongside the other previously identified 7 cell types

(Fig. 7A, C, D). In Normal tissue, all fibroblast subtypes broadcast ligands extensively to

generate a dense intercellular network. In nonobstructive HCM tissue, the intercellular

communication network for fibroblast subtypes shows a reduced number of broadcasting

ligands compared to Normal tissue, (1502 versus 2636 respectively; Fig. 7A, B). Fibroblast

cluster 2 generated the highest number of broadcasting ligands in both conditions. The largest

decreases in potential interactions occurred between fibroblast cluster 2 and fibroblast clusters

2 through 6 (Supplemental Table 7) and between fibroblast cluster 5 and fibroblast clusters 2

through 6 (Supplemental Table 8). In fibroblast cluster 2 from nonobstructive HCM tissue, there

was a disproportionate reduction in expression of cognate ligands for the ITGB1 receptor

(COL18A1, COL5A1, COL5A2, FBLN1, FBN1, HSPG2, LAMC1, LGALS3BP, NID1, THBS2) and also of

ligands for the LRP1 receptor (APP, C3, CALR, CTGF, HSPG2, LRPAP1, SERPINE2, SPERPING1,

TFPI). *ITGB1* and *LRP1* were expressed in both normal and nonobstructive HCM fibroblasts from

cluster 2. Interaction between fibroblast cluster 2 and fibroblast clusters 3-5 was reduced in

nonobstructive HCM primarily due to loss of the LRP1 receptor and several cognate ligands for

the ITGB1 receptor (COL18A1, COL5A1, COL5A2, FBLN1, FBN1, HSPG2, LAMC1, LGALS3BP, NID1,

THBS2). *ITGB1* was expressed in fibroblast clusters 3-5 in both normal and nonobstructive HCM

tissue.

Cardiomyocyte subtypes show subtype-specific changes in cell-cell communication

To better understand the interaction between the different cardiomyocyte populations and

other cell types in the IVS, we performed L-R analysis for all ten cardiomyocyte subtypes and

the other 7 cell types (Fig. 8). In nonobstructive HCM tissue, there is again a general decrease in

intercellular communication (2634 L-R pairs in normal, reduced to 2026 in nonobstructive HCM;

Fig. 8A, B), but the degree of reduction is lower than seen when subtypes are not considered or

when fibroblast subtypes are considered. The largest decreases occur in ligands broadcast from

endothelial cells and in receptors expressed by fibroblasts and the cardiomyocyte 4 cluster.

Notably, there are increases in ligands broadcast by cardiomyocyte clusters 1, 2, 5, 9 and by

smooth muscle cells and in receptors in cardiomyocyte clusters 1, 3 and 9 and dendritic cells in

nonobstructive HCM (Fig. 8B). The greatest reductions in intercellular L-R connections involve

fibroblasts broadcasting to fibroblasts and cardiomyocyte cluster 4 (Supplemental Table 9), and

from endothelial cells broadcasting to fibroblasts, cardiomyocyte cluster 4 and cardiomyocyte

cluster 8 (Supplemental Table 10). In both cases, reduction in intercellular communication is

due to loss of LRP1 receptor expression in fibroblasts as well as loss of ligands for ITGB1

(COL11A1, FBLN1, FBN1, HSPG2, LAMB1, LAMC1, NID1, VCAN) in fibroblasts and endothelial

cells. Notably, *ITGB1* is expressed in fibroblasts and cardiomyocyte clusters 4 and 8 in both

Normal tissue and nonobstructive HCM tissue. Increases in communication from cardiomyocyte

clusters 2, 5, fibroblasts and smooth muscle cells to cardiomyocyte cluster 9 is due to gain of

expression of *ITGB1* in cardiomyocyte cluster 9 (Supplemental Table 11). Increased

communication from cardiomyocyte cluster 5 to dendritic cells is also due to gain of expression

of *ITGB1* in dendritic cells (Supplemental Table 12).

Cardiomyocyte subtypes and fibroblast subtypes together show cell subtype-specific alterations

in cell-cell communication

Given that cardiomyocytes and fibroblasts are the most numerous cells in the heart and

demonstrate the most subtypes in our study, we examined the intercellular networks between

cardiomyocyte subtypes and fibroblast subtypes in normal tissue and nonobstructive HCM. The

total number of expressed ligand-receptor pairs in the Normal tissue was greater than in the

nonobstructive HCM tissue (3354 and 2399 expressed ligand-receptor pairs respectively, Fig. 9).

The largest decreases in cellular communication involved fibroblast cluster 5, through reduction

in both broadcasted ligands and expressed receptors. The largest reductions in L-R pairs

occurred between fibroblast clusters 2 or 5 and fibroblast clusters 2-6 (Supplemental Table 13)

and resulted from loss of ligands for ITGB1, which was still expressed in the recipient cells in

both normal and nonobstructive HCM, or from loss of the LRP1 receptor in recipient fibroblast

clusters except for fibroblast cluster 2. The largest increases in communication due to ligand

broadcasting involved cardiomyocyte clusters 2, 5 and 9 and increases due to receptor

expression involved cardiomyocyte clusters 1, 3, 9 and fibroblast cluster 1 (Fig. 9B). Increased

communication to cardiomyocyte cluster 9 from fibroblast clusters 1-5 and cardiomyocyte

clusters 2, 3 and 5 were due to gain of ITGB1 expression in cardiomyocyte cluster 9

(Supplemental Table 14).

Discussion

HCM has long been considered a disease of the sarcomere based on the association of

sarcomere gene mutations with HCM, but the contributions from other loci are increasingly

appreciated [2, 3], as are potential mechanisms aside from sarcomere dysfunction [26]. We have

previously examined single nuclei gene expression patterns in obstructive HCM. In this prior

study, we did not identify any HCM-specific cell populations but observed a profound reduction

in intercellular communication, especially in pathways mediated by ITGB1, and altered

extracellular matrix gene expression, which may explain some of the nonmyocyte phenotypes

seen in HCM such as fibrosis and link these phenotypes to alterations in mechanical signal

transduction [16]. In the current study, we performed a single nucleus transcriptome analysis of

tissue from patients with nonobstructive HCM, using tissue from the IVS harvested at the time

of cardiac transplantation. This patient population is distinct from those with obstructive HCM

in that they do not have LVOT obstruction and generally have more severe, intractable heart

failure that results in cardiac transplantation. Determining gene expression patterns at the

single cell level in nonobstructive HCM thus has the potential for facilitating precision medicine

approaches for this specific population, through overlapping and unique pathogenic

mechanisms relative to obstructive HCM.

The single nuclei gene expression patterns for nonobstructive HCM parallel those for

obstructive HCM in that there are no disease-specific cell clusters and there is a reduction in

intercellular communication, particularly in pathways involving ITGB1 and its associated ECM

ligands. As with obstructive HCM, changes in gene expression involve sarcomere genes known

to be associated with HCM and GO analysis indicates that gene expression changes are relevant

to the extracellular matrix and sarcomere function, indicating that these are common,

fundamental disease processes in HCM, regardless of LVOT obstruction. We have previously

noted that a reduction in ECM associated gene expression and molecular function in

obstructive HCM is counterintuitive based on the association between HCM and increased

fibrosis and have suggested that the reduction in gene expression may represent a negative

feedback loop that follows the accumulation of ECM protein in tissue [16]. Concordant findings in

nonobstructive HCM can be explained similarly. Precision medicine approaches that target

integrin signaling and ECM interaction may one day prove useful for both obstructive and

nonobstructive HCM.

A notable difference between obstructive and nonobstructive HCM in our current study,

however, involves the unexpected increases in communication between fibroblasts, smooth

muscle cells and pericytes with dendritic cells and between smooth muscle cells and leukocytes

in the nonobstructive HCM condition relative to the control condition. Immune cells have been

demonstrated to play important roles in development of cardiac hypertrophy and fibrosis in a

pressure overload model of rodent hypertrophy (reviewed in [27]). Dendritic cells function as

antigen presenting cells that activate T cell responses and depletion of these cells reduces

cardiomyocyte hypertrophy, cardiac fibrosis, LV remodeling and inflammatory cell infiltration

after pressure overload [28]. A role for dendritic cells in human heart failure is less well-

established, although a trend toward elevated numbers in blood has been reported [29]. Integrin-

mediated signaling has been shown to be an important determinant of dendritic cell function,

with ITGB1 determining dendritic morphology [30] and promoting an anti-inflammatory

phenotype in bone-marrow-derived dendritic cells [31]. Our data linking dendritic cells to

fibroblasts, smooth muscle cells and pericytes by ITGB1 signaling is novel and suggests an

important role for these cells in the pathological hypertrophy, cardiac fibrosis and vascular

abnormalities seen in nonobstructive HCM. Our additional novel observation that signal

transduction related molecular functions such as calcium channel activity and protein kinase A

activity are increased in dendritic cells from nonobstructive HCM hearts also provides additional

potential pathways for precision-medicine guided therapy for nonobstructive HCM.

We have previously noted extensive cardiomyocyte and fibroblast diversity in the human IVS,

likely due to the diverse origins of the cells within this anatomic region [15, 16]. We have also

noted that the different cardiomyocyte and fibroblast subtypes exhibit specific intercellular

communication profiles [16] and the phenomenon is observed again in this study. Specific

cardiomyocyte and fibroblast subtypes appear to adopt distinct functional roles relevant to the

disease process by shifting patterns of gene expression to increase or decrease interactions of

cell types. An ongoing challenge is to determine which of these shifts is most relevant to the

disease process and thus identify potential therapeutic targets. Future spatial transcriptomic

experiments assigning single cell populations to anatomic pathological features of HCM, such as

areas of myocyte disarray, fibrosis, focal myocyte hypertrophy, and vascular abnormalities will

likely be informative. Our study is the first to characterize transcription patterns in

nonobstructive HCM at single cell resolution and provides an important resource for future

investigation of the complex cellular interplay in nonobstructive HCM.

Methods

Study Patients, Sample Collection and Processing

A total of 6 patients with end stage, nonobstructive HCM scheduled for cardiac transplantation

were approached for written informed consent to allow their tissue to be used for research.

Those who consented underwent surgery and tissue was collected. Explanted heart tissue

sample processing was done as previously described [15, 16]. 100 mg of collected interventricular

septum tissue was minced into 1 mm^3 pieces, placed in 0.5 mL of CryoStor CS10 Freeze Media

(STEMCELL Technologies), and stored in a MrFrosty (ThermoFisher) at 4°C for 10 minutes and

then transferred to -80°C overnight. Bulk RNA was isolated from a piece of tissue using the

Qiagen RNeasy Plus Micro kit and then assessed on the Agilent Bioanalyzer 2100. Samples with

an RNA Integrity Number greater than 8.5 were used in library preparation. Sample collection

was approved by the Tufts University/Medical Center Health Sciences Institutional Review

Board under IRB protocol # 9487. Patient characteristics were obtained from the medical

record and are shown in Table 1. Tissue from organ donor patients without underlying cardiac

disease was obtained and processed as described previously [15].

Nuclei isolation, library preparation, and sequencing

Generation of single nuclei sequencing libraries was performed as previously described [15, 16].

Cryopreserved samples were thawed at 37°C and placed on ice. Nuclei were isolated via

Dounce homogenization as previously described [32]. Homogenates were filtered through a

438 Pluristrainer 10 µM cell strainer (Fisher Scientific) into a pre-chilled tube. Nuclei were pelleted

439 by centrifuging at 500 x g for 5 min at 4°C. Nuclei pellets were washed and pelleted according to

440 manufacturer protocol (10x Genomics). Nuclei were stained with trypan blue and counted on a

441 hemocytometer to determine concentration prior to loading of the 10x Chromium device and

442 samples were diluted to capture ~10,000 nuclei. Nuclei were separated into Gel Bead Emulsion

443 droplets using the 10x Chromium device according to the manufacturer protocol (10x

444 Genomics). Sequencing libraries were prepared using the Chromium Single Cell 3´ reagent V2

445 kit according to manufacturer's protocol. Libraries were multiplexed and sequenced on a

446 NovaSeq S4 (Illumina) to produce ~50,000 reads per nucleus. Single nuclei RNAseq data for

447 normal IVS tissue from 4 donors is available in the Gene Expression Omnibus database under

448 accession number GSE161921 [15]. Data for nonobstructive HCM IVS tissue and additional normal

449 heart donors is available under accession number GSE181764.

451 *Clustering of Cells by Gene Expression Pattern and Assignment of Cell Type Identity*

453 Clustering of cells and assignment of cell identity was done as previously described [15, 16].

454 Sequencing reads were processed using Cell Ranger version 6.0.1 [17]. The gene expression matrix

455 was subset to only include reads from the nuclear genome. Quality control (QC) filtering,

456 clustering, dimensionality reduction, visualization, and differential gene expression were

457 performed using the R package Seurat version 3.0. Each dataset was filtered so that genes that

458 were expressed in three nuclei or more were included in the final dataset. The dataset was

459 further sublet to exclude nuclei that had fewer than 200 genes expressed to remove droplets

containing only ambient RNA, and to exclude nuclei with greater than 2000 genes to remove

droplets that contained two nuclei. Datasets were individually normalized and integrated using

Seurat's SCTransform development workflow to reduce batch effects [18]. Optimal clustering

resolution was determined using Clustree version 0.4.3 [33] to identify the resolution where the

number of clusters stays stable and was determined to be 0.9 for the integrated dataset.

Assignment of cell identity to each cluster was performed using four separate analyses.

Expression of known cell-specific gene markers were used to identify major cell types, as done

previously [13, 15, 16, 34]. The top 20-30 differentially expressed genes in each cluster were also

compared with cell type gene expression markers from the PanglaoDB database

https://panglaodb.se [19] to independently assign cell type. Entire sets of differentially expressed

genes for each cluster were also subjected to Ingenuity Pathway Analysis [21] and their inferred

functions were used to identify cluster cell types independently. Upregulated genes from each

cluster were also subject to Gene Ontology biological process association using GoStats [20] and

these associations were used to refine cell type assignment further.

Trajectory Analysis and Identification of Differentially Expressed Genes

Trajectory analysis was performed using Monocle3 [22] to determine the relationship between

subtypes of cells identified in our clustering analysis as previously described [16]. Since our data

do not represent a developmental time course, we determined the root nodes for each subtype

by hierarchical clustering prior to generating trajectories and assigning pseudotime to each cell.

Each cell type was analyzed in three cohorts: 1. Normal and nonobstructive HCM cells together;

2. Normal cells alone; 3. Nonobstructive HCM cells alone. Once trajectories were established,

differential expression between Normal and HCM cells by cell type and cluster was performed

by fitting a generalized linear regression model to each gene according to the formula $\log(y_i) =$

$\beta_0 + \beta_t x_t$. The coefficients β_0 and β_t were extracted from each model and tested for significant

difference from zero using the Wald test, which assesses constraints on statistical parameters

based on the weighted distance between the unrestricted estimate and its hypothesized value

under the null hypothesis, where the weight is the precision of the estimate. A gene was

determined to be differentially expressed between Normal and HCM conditions in a cell type or

cluster if the Wald test produced an adjusted p-value ≤0.05.

Differentially expressed genes over trajectory paths in UMAP space (i.e., spatial

autocorrelation) was performed in Monocle3 using Moran's I statistic. Moran's I statistic is a

value that varies from -1 to 1, where -1 indicates perfect dispersion, 0 indicates no spatial

autocorrelation, and 1 indicates perfect positive autocorrelation (i.e., nearby cells in have

similar gene expression values in focal region of UMAP space). For each Normal and

nonobstructive HCM cell type, a gene was determined to be differentially expressed over space

if the associated Moran's I statistic value was positive, paired with a significant adjusted p-value

≤ 0.05, and expressed in ≥ 1% of associated cells. Since many genes showed differential

expression over space, further conservative filtering was performed in which genes with

Moran's I statistic available in a single class (i.e., Normal or HCM) were filtered by Moran's I

statistic values >0.1. For genes with Moran's I statistics available in both classes (i.e., Normal

and HCM), genes were filtered by an absolute difference >0.1. GO analysis of molecular

function and biological process associated with differentially expressed genes was done using

the online tools at uniprot.org/uniprotkb [35].

Analysis of Ligand-Receptor Pair Gene Expression to Discover Intercellular Communication

Pathways

To quantify potential cardiac cell-cell communication in Normal and HCM hearts, cell

communication networks were plotted in igraph version 1.2.6 [36] and compared on the basis of

ligand-receptor pair gene expression. Our cell-cell communication networks were derived as

described previously [23], using a list of 2557 human ligand-receptor pairs [24] combined with

another list of 3398 human ligand-receptor pairs [25], to give a total of 3627 unique human

ligand-receptor pairs, largely as described previously [16]. A ligand or receptor for each cell type

or cluster was considered expressed if the corresponding gene showed an above zero gene

count in ≥ 20% of cells in our snRNAseq data. We initially analyzed the potential signaling

interactions between the 8 cell types identified in our snRNAseq data. Lines in our cell networks

connect two cell types and represent expressed human ligand-receptor pairs (i.e., potential cell-

cell communication between a broadcasting (ligand) and recipient (receptor) cell types. Line

color in our networks represents the broadcasting ligand source. Line thickness is proportional

to the number of uniquely expressed ligand-receptor pairs. Cell-cell communication networks

were also analyzed by fibroblast cluster along with other cell types, by cardiomyocyte cluster

and other cell types and by fibroblast clusters and cardiomyocyte clusters. GO analysis of

differentially expressed ligand receptor pairs was performed using the R package clusterProfiler

[37].

Statistics

We used mixed effects models to analyze cell type specific differential expression, while taking

into account the variability between and within subjects. A sample size of 6 cases and 6

controls, with an average of 3,000 cells per subject, will provide 80% power to detect fold

change of expression ranging between 1.3 for an intracluster correlation f 0.01, and 2 for an

intracluster correlation of 0.1. The power calculations were pretty stable for sample sizes

ranging between 500 and 3000 cells per subject. We used a Bonferroni correction for 10,000

tests to fix the level of significance. The power calculations were conducted using Power

Analysis and Sample Size software (PASS).

Other statistical methods to cluster cells in UMAP space and control for batch effects using the

built-in functionality of Seurat [18], to determine cluster stability by Clustree [33] and to perform

Gene Ontology Analysis using well documented software programs [37] are described in above

methods sections and in cited references. Statistical methods to compare gene expression

along pseudotime trajectories using linear regression or spatial autocorrelation using the built-

in functionality of Monocle3 are described above and in the original cited reference [22].

Study Approval

Explanted HCM heart sample collection was approved by the Tufts University/Medical Center

Health Sciences Institutional Review Board under IRB protocol # 9487. All subjects gave their

informed consent for inclusion before they participated in the study. The study was conducted

in accordance with the Declaration of Helsinki. Unused donor hearts were obtained in

deidentified fashion from New England Donor Services under a Tufts University/Medical Center

Health Sciences IRB approved research protocol after being designated as not human subjects

research.

Author contributions:

Conceptualization: MTC

Data Curation: CJC, AL, GP, MTC

Formal Analysis: CJC, MTC

Methodology: CJC, AL, JA, GP, MTC

Investigation: AL, CJC, JA, GP, MTC

Visualization: CJC, AL, MTC

Funding acquisition: MTC, AL

Project administration: MTC

Resources: AL, MTC

Software: AL, CJC

Supervision: MTC

Writing – original draft: MTC

Writing – review & editing: AL, CJC, JA, GP, MTC

Acknowledgements

We thank Paola Sebastiani for helpful discussions regarding statistics.

Funding:

American Heart Association Innovative Project Award 18IPA34170294 (MTC)

References

1.   Thierfelder L, Watkins H, MacRae C, Lamas R, McKenna W, Vosberg HP, Seidman JG and
Seidman CE. Alpha-tropomyosin and cardiac troponin T mutations cause familial hypertrophic
cardiomyopathy: a disease of the sarcomere. *Cell*. 1994;77:701-12.
2.   Harper AR, Goel A, Grace C, Thomson KL, Petersen SE, Xu X, Waring A, Ormondroyd E,
Kramer CM, Ho CY, Neubauer S, Investigators H, Tadros R, Ware JS, Bezzina CR, Farrall M and
Watkins H. Common genetic variants and modifiable risk factors underpin hypertrophic
cardiomyopathy susceptibility and expressivity. *Nat Genet*. 2021;53:135-142.
3.   Tadros R, Francis C, Xu X, Vermeer AMC, Harper AR, Huurman R, Kelu Bisabu K, Walsh R,
Hoorntje ET, Te Rijdt WP, Buchan RJ, van Velzen HG, van Slegtenhorst MA, Vermeulen JM,
Offerhaus JA, Bai W, de Marvao A, Lahrouchi N, Beekman L, Karper JC, Veldink JH, Kayvanpour
E, Pantazis A, Baksi AJ, Whiffin N, Mazzarotto F, Sloane G, Suzuki H, Schneider-Luftman D, Elliott
P, Richard P, Ader F, Villard E, Lichtner P, Meitinger T, Tanck MWT, van Tintelen JP, Thain A,
McCarty D, Hegele RA, Roberts JD, Amyot J, Dube MP, Cadrin-Tourigny J, Giraldeau G, L'Allier
PL, Garceau P, Tardif JC, Boekholdt SM, Lumbers RT, Asselbergs FW, Barton PJR, Cook SA,
Prasad SK, O'Regan DP, van der Velden J, Verweij KJH, Talajic M, Lettre G, Pinto YM, Meder B,
Charron P, de Boer RA, Christiaans I, Michels M, Wilde AAM, Watkins H, Matthews PM, Ware JS
and Bezzina CR. Shared genetic pathways contribute to risk of hypertrophic and dilated
cardiomyopathies with opposite directions of effect. *Nat Genet*. 2021;53:128-134.
4.   Watkins H. Time to Think Differently About Sarcomere-Negative Hypertrophic
Cardiomyopathy. *Circulation*. 2021;143:2415-2417.
5.   Ho CY, Day SM, Ashley EA, Michels M, Pereira AC, Jacoby D, Cirino AL, Fox JC, Lakdawala
NK, Ware JS, Caleshu CA, Helms AS, Colan SD, Girolami F, Cecchi F, Seidman CE, Sajeev G,
Signorovitch J, Green EM and Olivotto I. Genotype and Lifetime Burden of Disease in
Hypertrophic Cardiomyopathy: Insights from the Sarcomeric Human Cardiomyopathy Registry
(SHaRe). *Circulation*. 2018;138:1387-1398.
6.   Kong P, Christia P and Frangogiannis NG. The pathogenesis of cardiac fibrosis. *Cell Mol*
Life Sci. 2014;71:549-74.
7.   Ma ZG, Yuan YP, Wu HM, Zhang X and Tang QZ. Cardiac fibrosis: new insights into the
pathogenesis. *Int J Biol Sci*. 2018;14:1645-1657.
8.   Nagaraju CK, Dries E, Gilbert G, Abdesselem M, Wang N, Amoni M, Driesen RB and
Sipido KR. Myofibroblast modulation of cardiac myocyte structure and function. *Sci Rep*.
2019;9:8879.
9.   O'Hanlon R, Grasso A, Roughton M, Moon JC, Clark S, Wage R, Webb J, Kulkarni M,
Dawson D, Sulaibeekh L, Chandrasekaran B, Bucciarelli-Ducci C, Pasquale F, Cowie MR,
McKenna WJ, Sheppard MN, Elliott PM, Pennell DJ and Prasad SK. Prognostic significance of
myocardial fibrosis in hypertrophic cardiomyopathy. *J Am Coll Cardiol*. 2010;56:867-74.
10.   Bruder O, Wagner A, Jensen CJ, Schneider S, Ong P, Kispert EM, Nassenstein K, Schlosser
T, Sabin GV, Sechtem U and Mahrholdt H. Myocardial scar visualized by cardiovascular
magnetic resonance imaging predicts major adverse events in patients with hypertrophic
cardiomyopathy. *J Am Coll Cardiol*. 2010;56:875-87.

11.   Ellims AH, Iles LM, Ling LH, Hare JL, Kaye DM and Taylor AJ. Diffuse myocardial fibrosis in
hypertrophic cardiomyopathy can be identified by cardiovascular magnetic resonance, and is
associated with left ventricular diastolic dysfunction. *J Cardiovasc Magn Reson*. 2012;14:76.
12.   Maron BJ and Longo DL. Clinical Course and Management of Hypertrophic
Cardiomyopathy. *New England Journal of Medicine*. 2018;379:655-668.
13.   Tucker NR, Chaffin M, Fleming SJ, Hall AW, Parsons VA, Bedi KC, Jr., Akkad AD, Herndon
CN, Arduini A, Papangeli I, Roselli C, Aguet F, Choi SH, Ardlie KG, Babadi M, Margulies KB,
Stegmann CM and Ellinor PT. Transcriptional and Cellular Diversity of the Human Heart.
Circulation. 2020;142:466-482.
14.   Litvinukova M, Talavera-Lopez C, Maatz H, Reichart D, Worth CL, Lindberg EL, Kanda M,
Polanski K, Heinig M, Lee M, Nadelmann ER, Roberts K, Tuck L, Fasouli ES, DeLaughter DM,
McDonough B, Wakimoto H, Gorham JM, Samari S, Mahbubani KT, Saeb-Parsy K, Patone G,
Boyle JJ, Zhang H, Zhang H, Viveiros A, Oudit GY, Bayraktar O, Seidman JG, Seidman CE, Noseda
M, Hubner N and Teichmann SA. Cells of the adult human heart. *Nature*. 2020;588:466-472.
15.   Larson A and Chin MT. A method for cryopreservation and single nucleus RNA-
sequencing of normal adult human interventricular septum heart tissue reveals cellular
diversity and function. *BMC Med Genomics*. 2021;14:161.
16.   Larson A, Codden CJ, Huggins GS, Rastegar H, Chen FY, Maron BJ, Rowin EJ, Maron MS
and Chin MT. Altered Intercellular Communication And Extracellular Matrix Signaling As A
Disease Mechanism In Human Hypertrophic Cardiomyopathy. *Preprint (version 1) available at*
https://papersssrncom/sol3/papersscfm?abstract_id=3965237. 2021.
17.   Zheng GX, Terry JM, Belgrader P, Ryvkin P, Bent ZW, Wilson R, Ziraldo SB, Wheeler TD,
McDermott GP, Zhu J, Gregory MT, Shuga J, Montesclaros L, Underwood JG, Masquelier DA,
Nishimura SY, Schnall-Levin M, Wyatt PW, Hindson CM, Bharadwaj R, Wong A, Ness KD, Beppu
LW, Deeg HJ, McFarland C, Loeb KR, Valente WJ, Ericson NG, Stevens EA, Radich JP, Mikkelsen
TS, Hindson BJ and Bielas JH. Massively parallel digital transcriptional profiling of single cells.
Nat Commun. 2017;8:14049.
18.   Butler A, Hoffman P, Smibert P, Papalexi E and Satija R. Integrating single-cell
transcriptomic data across different conditions, technologies, and species. *Nat Biotechnol*.
2018;36:411-420.
19.   Franzen O, Gan LM and Bjorkegren JLM. PanglaoDB: a web server for exploration of
mouse and human single-cell RNA sequencing data. *Database (Oxford)*. 2019;2019.
20.   Falcon S and Gentleman R. Using GOstats to test gene lists for GO term association.
Bioinformatics. 2007;23:257-8.
21.   Kramer A, Green J, Pollard J, Jr. and Tugendreich S. Causal analysis approaches in
Ingenuity Pathway Analysis. *Bioinformatics*. 2014;30:523-30.
22.   Cao J, Spielmann M, Qiu X, Huang X, Ibrahim DM, Hill AJ, Zhang F, Mundlos S,
Christiansen L, Steemers FJ, Trapnell C and Shendure J. The single-cell transcriptional landscape
of mammalian organogenesis. *Nature*. 2019;566:496-502.
23.   Skelly DA, Squiers GT, McLellan MA, Bolisetty MT, Robson P, Rosenthal NA and Pinto AR.
Single-Cell Transcriptional Profiling Reveals Cellular Diversity and Intercommunication in the
Mouse Heart. *Cell Rep*. 2018;22:600-610.

24. Ramilowski JA, Goldberg T, Harshbarger J, Kloppmann E, Lizio M, Satagopam VP, Itoh M,
Kawaji H, Carninci P, Rost B and Forrest AR. A draft network of ligand-receptor-mediated
multicellular signalling in human. *Nat Commun*. 2015;6:7866.
25. Shao X, Liao J, Li C, Lu X, Cheng J and Fan X. CellTalkDB: a manually curated database of
ligand-receptor interactions in humans and mice. *Brief Bioinform*. 2020.
26. Chou C and Chin MT. Pathogenic Mechanisms of Hypertrophic Cardiomyopathy beyond
Sarcomere Dysfunction. *International Journal of Molecular Sciences*. 2021;22:8933.
27. Liu X, Shi GP and Guo J. Innate Immune Cells in Pressure Overload-Induced Cardiac
Hypertrophy and Remodeling. *Front Cell Dev Biol*. 2021;9:659666.
28. Wang H, Kwak D, Fassett J, Liu X, Yao W, Weng X, Xu X, Xu Y, Bache RJ, Mueller DL and
Chen Y. Role of bone marrow-derived CD11c(+) dendritic cells in systolic overload-induced left
ventricular inflammation, fibrosis and hypertrophy. *Basic Res Cardiol*. 2017;112:25.
29. Athanassopoulos P, Balk AH, Vaessen LM, Caliskan K, Takkenberg JJ, Weimar W and
Bogers AJ. Blood dendritic cell levels and phenotypic characteristics in relation to etiology of
end-stage heart failure: implications for dilated cardiomyopathy. *Int J Cardiol*. 2009;131:246-56.
30. Swetman Andersen CA, Handley M, Pollara G, Ridley AJ, Katz DR and Chain BM. beta1-
Integrins determine the dendritic morphology which enhances DC-SIGN-mediated particle
capture by dendritic cells. *Int Immunol*. 2006;18:1295-303.
31. Yokota-Nakatsuma A, Ohoka Y, Takeuchi H, Song SY and Iwata M. Beta 1-integrin
ligation and TLR ligation enhance GM-CSF-induced ALDH1A2 expression in dendritic cells, but
differentially regulate their anti-inflammatory properties. *Sci Rep*. 2016;6:37914.
32. Krishnaswami SR, Grindberg RV, Novotny M, Venepally P, Lacar B, Bhutani K, Linker SB,
Pham S, Erwin JA, Miller JA, Hodge R, McCarthy JK, Kelder M, McCorrison J, Aevermann BD,
Fuertes FD, Scheuermann RH, Lee J, Lein ES, Schork N, McConnell MJ, Gage FH and Lasken RS.
Using single nuclei for RNA-seq to capture the transcriptome of postmortem neurons. *Nat
Protoc*. 2016;11:499-524.
33. Zappia L and Oshlack A. Clustering trees: a visualization for evaluating clusterings at
multiple resolutions. *Gigascience*. 2018;7.
34. McLellan MA, Skelly DA, Dona MSI, Squiers GT, Farrugia GE, Gaynor TL, Cohen CD,
Pandey R, Diep H, Vinh A, Rosenthal NA and Pinto AR. High-Resolution Transcriptomic Profiling
of the Heart During Chronic Stress Reveals Cellular Drivers of Cardiac Fibrosis and Hypertrophy.
Circulation. 2020;142:1448-1463.
35. UniProt C. UniProt: the universal protein knowledgebase in 2021. *Nucleic Acids Res*.
2021;49:D480-D489.
36. Csardi G and Nepusz T. The igraph software package for complex network research.
InterJournal. 2006;Complex Systems:1695.
37. Yu G, Wang LG, Han Y and He QY. clusterProfiler: an R package for comparing biological
themes among gene clusters. *OMICS*. 2012;16:284-7.
708

Fig. 1. Single nuclei RNA-seq of Normal and HCM IVS Tissue Reveals Cellular Diversity but No

HCM-associated Cell Types. A. UMAP plot of 22 distinct cell clusters identified in the combined

Normal and nonobstructive HCM dataset. **B**. Separating the cell clusters by condition does not

identify HCM-specific cell types. **C**. Cluster distribution in each Normal sample. D. Cluster

distribution in each nonobstructive HCM sample.

Fig. 2. Biomarker Expression and Cell Identification Assignments for each Cluster. A.

Biomarkers used to assign cell identity and their relative expression in each cluster. **B**. UMAP

plot of IVS tissue clusters with cell assignment labels.

Fig. 3. Gene Ontology Enrichment Analysis of Differentially Expressed Genes in

nonobstructive HCM. **A**. GO enrichment analysis of all differentially expressed genes in HCM

from Table 3. **B**. GO enrichment analysis of Table 3 genes increased in nonobstructive HCM. **C**.

GO enrichment analysis of Table 3 genes decreased in nonobstructive HCM.

Cell Group	Total expressed L		Total expressed R	
	Normal	Non-obstructive	Normal	Non-obstructive
Cardiomyocyte	63	42	104	49
Fibroblast	164	106	117	49
Endothelial	108	33	98	49
Pericyte	74	66	100	55
Dendritic	76	26	30	49
Leukocyte	88	33	68	56
Smooth Muscle	68	74	99	49
Neuronal	69	25	94	49
Sum	710	405	710	405

Fig. 4. Intercellular communication networks are reduced in nonobstructive HCM. **A**. Cell-cell communication networks between cardiac cell types in normal control (left) and nonobstructive HCM (right) conditions. Line color indicates ligand broadcast by the cell population with the same color. Lines connect to cell types which expressed cognate receptors. Line thickness is proportional to the number of uniquely expressed ligand-receptor pairs. Loops indicates communication within a cell type. **B**. Quantity of ligands and receptors in expressed ligand-receptor pairs described by cell type and condition (Normal or nonobstructive HCM). **C**., **D**. Cell-cell communication networks broken down by cell type in normal control (**C**) and nonobstructive HCM (**D**) conditions. Figure formatting follows panel A. Numbers indicate the quantity of uniquely expressed ligand-receptor pairs between the broadcasting cell type (expressing ligand) and receiving cell type (expressing receptor).

Fig. 5. Bar plot representing the total count of ligands (in expressed ligand-receptor pairs)

associated with different cellular processes in Normal and nonobstructive HCM IVS Cells. Bar

color distinguishes ligand count in normal or nonobstructive HCM conditions. **A**. Comparison of

molecular functions across all cell types. **B**. Comparison in cardiomyocytes. **C**. Fibroblasts. **D**.

Endothelial Cells. **E**. Pericytes. **F.** Dendritic Cells. **G.** Leukocytes. **H**. Smooth Muscle Cells. **I**.

Neurons.

Fig. 6. Bar plot representing the total count of receptors (in expressed ligand-receptor pairs) associated with different cellular processes in Normal and nonobstructive HCM IVS Cells. Bar

756   color distinguishes receptor count in normal or nonobstructive HCM conditions. **A**. Comparison

757   of molecular functions across all cell types. **B**. Comparison in cardiomyocytes. **C**. Fibroblasts. **D**.

758   Endothelial Cells. **E**. Pericytes. **F.** Dendritic Cells. **G.** Leukocytes. **H**. Smooth Muscle Cells. **I**.

759   Neurons.

	Total expressed L		Total expressed R	
Cell Group	Normal	Non-obstructive	Normal	Non-obstructive
Cardiomyocyte	109	72	213	109
Fibroblast 1	239	163	95	109
Fibroblast 2	401	256	286	171
Fibroblast 3	266	188	252	109
Fibroblast 4	242	135	252	109
Fibroblast 5	241	58	275	109
Fibroblast 6	299	191	252	109
Endothelial	198	58	209	110
Pericyte	140	110	211	120
Dendritic	122	46	54	109
Leukocyte	142	57	133	120
Smooth Muscle	118	123	205	109
Neuronal	119	45	199	109
Sum	2636	1502	2636	1502

Fig. 7. Cell-cell communication networks between fibroblast subtypes and other heart cells in normal control and nonobstructive HCM conditions. A. Comparison of Normal (left) and nonobstructive HCM (right) communication networks. Line color indicates ligand broadcast by the cell population with the same color. Lines connect to cell types which expressed cognate receptors. Line thickness is proportional to the number of uniquely expressed ligand-receptor pairs. Loops indicates communication within a cell type. **B.** Quantity of ligands and receptors in

769   expressed ligand-receptor pairs described by cell type and condition (Normal or nonobstructive

770   HCM). **C, D.** Cell-cell communication networks broken down by cell type and fibroblast cluster

771   in normal control (**C**) and nonobstructive HCM (**D**) conditions. Figure formatting follows panel A.

772   Numbers indicate the quantity of uniquely expressed ligand-receptor pairs between the

773   broadcasting cell type (expressing ligand) and receiving cell type (expressing receptor).

Fig. 8. Cell-cell communication networks between cardiomyocyte subtypes and other heart cells in normal control and nonobstructive HCM conditions. A. Comparison of Normal (left) and nonobstructive HCM (right) communication networks. Line color indicates ligand broadcast by the cell population with the same color. Lines connect to cell types which expressed cognate receptors. Line thickness is proportional to the number of uniquely expressed ligand-receptor pairs. Loops indicates communication within a cell type. **B.** Quantity of ligands and receptors in expressed ligand-receptor pairs described by cell type and condition (Normal or nonobstructive HCM). **C, D.** Cell-cell communication networks broken down by cell type and cardiomyocyte cluster in normal control (**C**) and nonobstructive HCM (**D**) conditions. Figure formatting follows

Cell Group	Total expressed L		Total expressed R	
	Normal	Non-obstructive	Normal	Non-obstructive
Cardiomyocyte 1	47	49	40	41
Cardiomyocyte 2	145	174	164	106
Cardiomyocyte 3	168	130	220	229
Cardiomyocyte 4	97	88	203	103
Cardiomyocyte 5	194	266	169	144
Cardiomyocyte 6	113	83	183	106
Cardiomyocyte 7	114	99	201	154
Cardiomyocyte 8	219	124	202	129
Cardiomyocyte 9	61	83	40	154
Cardiomyocyte 10	104	81	166	106
Fibroblast	338	231	202	103
Endothelial	229	81	164	104
Pericyte	154	143	174	118
Dendritic	168	73	55	105
Leukocyte	194	77	118	118
Smooth Muscle	144	173	173	103
Neuronal	145	71	160	103
Sum	**2634**	**2026**	**2634**	**2026**

786   panel A. Numbers indicate the quantity of uniquely expressed ligand-receptor pairs between

787   the broadcasting cell type (expressing ligand) and receiving cell type (expressing receptor).

Cell Group	Total expressed L		Total expressed R	
	Normal	Non-obstructive	Normal	Non-obstructive
Cardiomyocyte 1	47	45	40	44
Cardiomyocyte 2	152	167	201	142
Cardiomyocyte 3	171	124	256	263
Cardiomyocyte 4	104	86	241	132
Cardiomyocyte 5	202	256	217	171
Cardiomyocyte 6	121	81	221	134
Cardiomyocyte 7	117	96	237	179
Cardiomyocyte 8	217	121	242	156
Cardiomyocyte 9	65	80	40	179
Cardiomyocyte 10	104	79	205	138
Fibroblast 1	298	206	104	132
Fibroblast 2	481	325	289	201
Fibroblast 3	330	237	260	132
Fibroblast 4	299	171	260	132
Fibroblast 5	293	79	281	132
Fibroblast 6	353	246	260	132
Sum	3354	2399	3354	2399

Fig. 9. Cell-cell communication networks between cardiac fibroblast and cardiomyocyte subtypes in normal control and HCM conditions. A. Overall communication network between cardiomyocytes and fibroblasts. Line color indicates ligand broadcast by the cell population with the same color. Lines connect to cell types which expressed cognate receptors. Line thickness is proportional to the number of uniquely expressed ligand-receptor pairs. Loops indicates communication within a cell type. **B.** Quantity of ligands and receptors in expressed ligand-receptor pairs described by cell type and condition (Normal or nonobstructive HCM). **C, D.** Cell-cell communication networks broken down by cardiomyocyte cluster and fibroblast cluster in normal control (**C**) and nonobstructive HCM (**D**) conditions. Figure formatting follows panel A.

800   Numbers indicate the quantity of uniquely expressed ligand-receptor pairs between the

801   broadcasting cell type (expressing ligand) and receiving cell type (expressing receptor).

803   Table 1. HCM Patient Characteristics

Patient	2833	2890	2891	2918	2930	5171
Demographics						
age at transplant	21-25	61-65	46-50	61-65	36-40	66-70
female	yes	yes	no	yes	yes	yes
nyha class>3	yes	yes	yes	yes	yes	yes
Med Hx						
Prior AF	no	yes	yes	yes	yes	no
Prior VT/VF	yes	no	no	no	no	yes
Prior NS VT	no	no	no	no	no	yes
Prior syncope	yes	no	yes	no	no	no
Fam Hx SCD	no	no	yes	yes	no	yes
Fam Hx HCM	no	no	yes	yes	yes	yes
Comorbidities	none	HTN, HLD, COPD, DM2, CHB, OA, prior myectomy	OSA, Sarcoidosis	CAD, hypothyroidism	hypothyroidism, apical hypertrophy	asthma, HLD, apical aneurysm
Meds						
beta blocker	yes	yes	no	yes	no	yes
calcium channel blocker	no	no	no	no	no	no
ACE or ARB	no	no	no	yes	no	yes
Diuretic Use	yes	yes	yes	yes	yes	yes
loop diuretic	yes	yes	yes	yes	yes	yes
thiazide	no	yes	yes	no	no	yes
potassium sparing	yes	yes	yes	yes	yes	yes
disopyramide	no	no	no	no	no	no
amiodarone	no	no	no	no	yes	no
milrinone	yes	yes	yes	yes	no	yes
dofetilide	no	no	yes	no	no	no
ICD	yes	yes	yes	yes	yes	yes
Physiological measurements						
LA size (mm)	47	37	36	64	33	51
systolic blood pressure	95	103	120	87	99	130
diastolic blood pressure	57	56	54	66	49	67
IVS thickness (mm)	26	11 (prior myectomy)	13	18	9.5	9
Posterior wall thickness	20	0.88	13	16	7.7	9
LVEF (%)	15-20	65	60	45	65	25-30
LVEDD (mm)	51	46	45	41	45	57
LVESD (m)	49	29	28	35	49	41
MR	mild	trace	no	trace	mild	mild
LGE on MRI	24%	none	ND	ND	none	ND
Pathogenic HCM Variant	NF	NF	MYH7	NF	NF	MYH7

804
805

806   Table 2. Organ Donor Characteristics

Donor	2867	2879	2880	2884	2900	3045
age	21-25	56-60	41-45	41-45	46-50	66-70
female	yes	no	no	yes	no	yes
cause of death	asphyxiation	CVA	head trauma	seizure	overdose	CVA
cardiac risk factors	none	none	none	HTN, Tobacco	none	HLD
CAD	not assessed	20% LAD	not assessed	not assessed	not assessed	not assessed
LVEF	81%	60%	not assessed	55%	not assessed	70%
Medications	antidepressants, OCP	none	unknown	unknown	unknown	statin, levothyroxine

809   Table 3. Differentially Expressed Genes in Nonobstructive HCM with Pronounced Changes in

810   Spatial Expression

	Gene of Interest	Affected Cell Group	Expression in Non-obstructive HCM	Established HCM Gene
1	ABCA10	Cardiomyocyte, Fibroblast	Decreased	
2	ABCA6	Cardiomyocyte	Decreased	
3	ABCA8	Cardiomyocyte	Decreased	
4	AC010680.1	Cardiomyocyte	Increased	
5	AC010680.5	Cardiomyocyte	Increased	
6	ADH1B	Cardiomyocyte	Decreased	
7	AGT	Endothelial, Pericyte	Decreased	
8	C1R	Fibroblast	Decreased	
9	C1S	Fibroblast	Decreased	
10	CCL21	Endothelial	Decreased	
11	CD74	Dendritic	Decreased	
12	COL1A2	Neuronal	Decreased	
13	CPE	Pericyte	Decreased	
14	EMC10	Cardiomyocyte	Decreased	
15	FABP4	Endothelial, Pericyte	Decreased	
16	FBLN2	Fibroblast	Decreased	
17	HES1	Fibroblast	Decreased	
18	HES4	Smooth Muscle	Decreased	
19	HLA-DRA	Dendritic	Decreased	
20	HLA-DRB1	Dendritic	Decreased	
21	IGFBP5	Endothelial	Decreased	
22	MEG3	Cardiomyocyte, Fibroblast	Decreased	
23	MMRN1	Endothelial	Decreased	
24	MS4A6A	Dendritic	Decreased	
25	MYH7	Neuronal	Decreased	Yes
26	MYH7B	Cardiomyocyte	Decreased	
27	MYL2	Cardiomyocyte	Increased	Yes
28	NDUFA4L2	Pericyte	Decreased	
29	NEBL	Cardiomyocyte	Increased	
30	NPPB	Cardiomyocyte	Decreased	
31	PDGFRB	Pericyte, Smooth Muscle	Decreased	
32	PLA2G2A	Cardiomyocyte	Decreased	
33	PTGIR	Cardiomyocyte	Decreased	
34	RP11-394O4.5	Smooth Muscle	Decreased	
35	RP11-532N4.2	Cardiomyocyte	Decreased	
36	SAT1	Dendritic	Decreased	
37	SLC8A1	Cardiomyocyte	Decreased	
38	SORBS2	Cardiomyocyte	Decreased	
39	SPARC	Neuronal	Decreased	
40	SPP1	Neuronal	Decreased	
41	TFPI	Endothelial	Decreased	
42	TMSB4X	Endothelial	Decreased	
43	TNNT2	Dendritic, Neuronal	Decreased	Yes
44	TTN	Neuronal	Increased	